Tumor Biology

, Volume 37, Issue 7, pp 9001–9007 | Cite as

miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma

  • Shuguang Zhou
  • Bing Wang
  • Jun Hu
  • Yucheng Zhou
  • Mengzhen Jiang
  • Mingyu Wu
  • Liming Qin
  • Xuming Yang
Original Article


MicroRNAs (miRNAs) are a new class of prognostic and diagnostic biomarkers for many cancers. Recent studies have shown that miRNAs are highly stable in plasma/serum. The aim of this study was to investigate the role of miR-421 in osteosarcoma. We found that the serum expression levels of miR-421 were significantly higher in osteosarcoma patients than those in healthy volunteers. Moreover, miR-421 expression was significantly higher in osteosarcoma tissues compared with that in the adjacent normal tissues. Meanwhile, the expression of miR-421 was upregulated in 90 % (36/40) osteosarcoma tissues compared to non-tumor tissues. More importantly, the expression levels of miR-421 in osteosarcoma tissues were correlated with those in patients’ serum. In addition, patients with high miR-421 expression had shorter overall survival (OS) than those with low expressions. We also found that overexpression of miR-421 promoted osteosarcoma cell line MG-63 proliferation, migration, and invasion. In conclusion, miR-421 expression levels were upregulated in osteosarcoma tissue and serum and it may be a useful marker for diagnosis of osteosarcoma.


Osteosarcoma MicroRNAs miR-421 Serum miRNA Invasion 

Supplementary material

13277_2015_4578_MOESM1_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)


  1. 1.
    Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif. 2014;47(5):427–34. doi: 10.1111/cpr.12129.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ, Tang CH. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 2014;5(11):3800–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS One. 2013;8(1):e53906. doi: 10.1371/journal.pone.0053906.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PloS One. 2012;7(3):e33778. doi: 10.1371/journal.pone.0033778.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PloS One. 2012;7(10):e48086. doi: 10.1371/journal.pone.0048086.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77. doi: 10.1158/0008-5472.CAN-11-2663.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105(7):755–62. doi: 10.1111/cas.12436.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li Y, Zhang J, Zhang L, Si M, Yin H, Li J. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis. 2013;34(7):1601–10. doi: 10.1093/carcin/bgt065.CrossRefPubMedGoogle Scholar
  9. 9.
    Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 2012;126(7):840–50. doi: 10.1161/CIRCULATIONAHA.112.094524.CrossRefPubMedGoogle Scholar
  10. 10.
    Martinez-Pacheco M, Hidalgo-Miranda A, Romero-Cordoba S, Valverde M, Rojas E. MRNA and miRNA expression patterns associated to pathways linked to metal mixture health effects. Gene. 2014;533(2):508–14. doi: 10.1016/j.gene.2013.09.049.CrossRefPubMedGoogle Scholar
  11. 11.
    Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatol. 2009;49(4):1194–202. doi: 10.1002/hep.22757.CrossRefGoogle Scholar
  12. 12.
    Yu L, Ding GF, He C, Sun L, Jiang Y, Zhu L. MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PloS One. 2014;9(3):e91661. doi: 10.1371/journal.pone.0091661.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015. doi:  10.1111/cpr.12180.
  14. 14.
    Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48(1):1–6. doi: 10.1111/cpr.12160.CrossRefPubMedGoogle Scholar
  15. 15.
    Yu X, Li Z, Liu J. MiRNAs in primary cutaneous lymphomas. Cell Prolif. 2015. doi:  10.1111/cpr.12179.
  16. 16.
    Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt Pathway by Targeting HOXD10 in intervetebral Disc Degeneration. PloS One. 2013;8(12):e83080. doi: 10.1371/journal.pone.0083080.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 2012;45(1):32–8. doi: 10.1111/j.1365-2184.2011.00798.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Li M, Yu M, Liu C, Zhu H, He X, Peng S, et al. miR-34c works downstream of p53 leading to dairy goat male germline stem-cell (mGSCs) apoptosis. Cell Prolif. 2013;46(2):223–31. doi: 10.1111/cpr.12013.CrossRefPubMedGoogle Scholar
  19. 19.
    Fu LL, Zhao X, Xu HL, Wen X, Wang SY, Liu B, et al. Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death. Cell Prolif. 2012;45(5):477–85. doi: 10.1111/j.1365-2184.2012.00840.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46(4):436–46. doi: 10.1111/cpr.12038.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2012;20(4):139–47.CrossRefPubMedGoogle Scholar
  22. 22.
    Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2013;21(2):83–91. doi: 10.3727/096504013X13775486749218.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res. 2012;20(5-6):197–203.CrossRefPubMedGoogle Scholar
  24. 24.
    Xiao X, Tang C, Xiao S, Fu C, Yu P. Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res. 2013;20(11):537–44. doi: 10.3727/096504013X13775486749335.CrossRefPubMedGoogle Scholar
  25. 25.
    Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PloS One. 2012;7(8):e42895. doi: 10.1371/journal.pone.0042895.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PloS One. 2012;7(3):e34546. doi: 10.1371/journal.pone.0034546.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ma R, Yan W, Zhang G, Lv H, Liu Z, Fang F, et al. Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. PloS One. 2012;7(6):e38096. doi: 10.1371/journal.pone.0038096.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gong M, Ma J, Guillemette R, Zhou M, Yang Y, Hock JM, et al. MiR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014;12(1):101–10. doi: 10.1158/1541-7786.MCR-13-0136.CrossRefPubMedGoogle Scholar
  29. 29.
    Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol. 2012;235(2):491–6. doi: 10.1016/j.expneurol.2011.11.026.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Report. 2012;5(6):1514–20. doi: 10.3892/mmr.2012.828.Google Scholar
  31. 31.
    Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59. doi: 10.1093/jnci/djt101.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Gao Y, Luo LH, Li S, Yang C. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun. 2014;444(2):230–4. doi: 10.1016/j.bbrc.2014.01.061.CrossRefPubMedGoogle Scholar
  33. 33.
    Lei P, Xie J, Wang L, Yang X, Dai Z, Hu Y. microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep. 2014;10(1):155–60. doi: 10.3892/mmr.2014.2195.PubMedGoogle Scholar
  34. 34.
    Huang YZ, Zhang J, Shao HY, Chen JP, Zhao HY. MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi:  10.1007/s13277-015-3290-9.
  35. 35.
    Zhang Y, Duan G, Feng S. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun. 2015;459(3):367–73. doi: 10.1016/j.bbrc.2015.02.101.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen L, Tang Y, Wang J, Yan Z, Xu R. miR-421 induces cell proliferation and apoptosis resistance in human nasopharyngeal carcinoma via downregulation of FOXO4. Biochem Biophys Res Commun. 2013;435(4):745–50. doi: 10.1016/j.bbrc.2013.05.056.CrossRefPubMedGoogle Scholar
  37. 37.
    Wu JH, Yao YL, Gu T, Wang ZY, Pu XY, Sun WW, et al. MiR-421 regulates apoptosis of BGC-823 gastric cancer cells by targeting caspase-3. Asian Pac J Cancer Prev. 2014;15(13):5463–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol. 2010;45(1):17–23. doi: 10.1007/s00535-009-0135-6.CrossRefPubMedGoogle Scholar
  39. 39.
    Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Commun. 2011;406(4):552–7. doi: 10.1016/j.bbrc.2011.02.086.CrossRefPubMedGoogle Scholar
  40. 40.
    Wu J, Li G, Yao Y, Wang Z, Sun W, Wang J. MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer. Biomarker. 2015;20(1):58–63. doi: 10.3109/1354750X.2014.992812.CrossRefGoogle Scholar
  41. 41.
    Cai H, Zhao H, Tang J, Wu H. Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res. 2015;194(2):505–10. doi: 10.1016/j.jss.2014.11.025.CrossRefPubMedGoogle Scholar
  42. 42.
    Zhang C, Yao C, Li H, Wang G, He X. Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. Int J Clin Exp Pathol. 2014;7(7):4194–203.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. Journal of translational medicine. 2012;10:55. doi: 10.1186/1479-5876-10-55.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev Anticancer Ther. 2012;12(2):283–8. doi: 10.1586/era.11.197.CrossRefPubMedGoogle Scholar
  45. 45.
    Hong Q, Fang J, Pang Y, Zheng J. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014;31(8):37. doi: 10.1007/s12032-014-0037-1.CrossRefPubMedGoogle Scholar
  46. 46.
    Yuan J, Chen L, Chen X, Sun W, Zhou X. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 2012;40(6):2090–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Wang RJ, Zheng YH, Wang P, Zhang JZ. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(1):765–71.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012;40(3):859–66.CrossRefPubMedGoogle Scholar
  49. 49.
    Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012;12(4):199–204. doi: 10.3233/CBM-130308.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shuguang Zhou
    • 1
    • 2
  • Bing Wang
    • 1
  • Jun Hu
    • 1
    • 3
  • Yucheng Zhou
    • 1
    • 4
  • Mengzhen Jiang
    • 5
  • Mingyu Wu
    • 2
  • Liming Qin
    • 2
  • Xuming Yang
    • 6
  1. 1.Department of Spine SurgeryThe Second Xiangya Hospital of Central South UniversityChangshaChina
  2. 2.Department of OrthopedicsThe Affiliated Hospital of Hunan University of Medicine and The Third People’s Hospital of HuaihuaHuaihuaChina
  3. 3.Department of OrthopedicsThe First Hospital of KunmingKunmingChina
  4. 4.Department of OrthopedicsThe People’s Hospital of QingyuanQingyuanChina
  5. 5.Department of GastroenterologyThe Affiliated Hospital of Hunan University of MedicineHuaihuaChina
  6. 6.Department of Spine SurgeryYan’an Hospital of KunmingKunmingChina

Personalised recommendations